Keurig Dr Pepper vs AbbVie

Side-by-side comparison of AI visibility scores, market position, and capabilities

AbbVie leads in AI visibility (90 vs 82)

Keurig Dr Pepper

LeaderConsumer Goods

Enterprise

Burlington MA beverages (NASDAQ: KDP) at $15.35B FY2024 revenue (+3.6%); Dr Pepper/7UP/Snapple + Keurig K-Cup, 82% FCF growth, 2025 guidance mid-single-digit growth competing with Coca-Cola and PepsiCo.

AI VisibilityBeta
Overall Score
A82
Category Rank
#59 of 290
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
91
Gemini
77

About

Keurig Dr Pepper Inc. is a Burlington, Massachusetts-based beverage company — publicly traded on NASDAQ (NASDAQ: KDP) as an S&P 500 Consumer Staples component — manufacturing, marketing, and distributing hot beverages (coffee through the Keurig single-serve system and Green Mountain roasted coffee brands), cold beverages (Dr Pepper, 7UP, Snapple, Canada Dry, A&W, Sunkist, Bai, Core, Clamato, Mott's, Hawaiian Punch, Penafiel), and producing/selling the Keurig K-Cup system (over 500 varieties of licensed K-Cup pods from 75+ coffee brands) through approximately 27,000 employees. In fiscal year 2024, Keurig Dr Pepper reported revenue of $15.35 billion (+3.6% year-over-year), adjusted diluted EPS growth of 8%, operating cash flow growth of 67% to $2.2 billion, and free cash flow growth of 82% to $1.7 billion. For 2025, KDP guided mid-single-digit net sales growth and high-single-digit adjusted EPS growth, reflecting continued volume growth in both the cold beverages portfolio and Keurig brewer and pod sales recovery. CEO Tim Cofer, who joined from Mondelez International in 2023, has prioritized revenue management (balancing price and volume), operational efficiency, and brand investment across KDP's portfolio of over 125 owned, licensed, and partner brands. Keurig Dr Pepper was formed through the 2018 merger of Keurig Green Mountain (coffee systems) and Dr Pepper Snapple Group (beverages), controlled by JAB Holding Company (a Luxembourg-based holding company of the Reimann family).

Full profile

AbbVie

LeaderHealthcare

General

Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.

AI VisibilityBeta
Overall Score
A90
Category Rank
#9 of 1167
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
99
Gemini
83

About

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.

Full profile

AI Visibility Head-to-Head

82
Overall Score
90
#59
Category Rank
#9
60
AI Consensus
60
stable
Trend
stable
83
ChatGPT
99
91
Perplexity
99
77
Gemini
83
79
Claude
96
74
Grok
95

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.